RxDoctor Payments Data

Arwa Al-Bedour, MD

Pulmonary Disease · Madison, WINPI 1174810121

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (44.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Intuitive Surgical at 58.5% of the total. Reporting peaked in 2023 at $5,513 and has fallen 99.6% since, to $20 in 2025.

$6,707in general payments, 2019–2025

Across 47 payments — averaging $142.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Olympus Corporation Of The Americas$1K
  • Merit Medical Systems Inc$458
  • Abiomed$275
  • United Therapeutics Corporation$267
  • Johnson & Johnson$157
  • plus $328 from 8 others

What the payments were for

  • Travel & lodging$2,46137%
  • Food & beverage$1,24619%
  • Education$3,00045%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,707 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$19,460
Medicare patients
74
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,736
Spiriva RespimatTiotropium Bromide14$10,022
Varenicline Tartrate15$2,678
Albuterol Sulfate HfaAlbuterol Sulfate41$1,180
Prednisone21$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$19$16,73627 claims
Boehringer IngelheimSpiriva Respimat$81$10,02214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →